Inhibitory Effect of the HASPIN Inhibitor CHR-6494 on BxPC-3-Luc, A Luciferase-Expressing Pancreatic Cancer Cell Line.

Authors :: Tanaka H
Nishida-Fukuda H
Wada M
Tokuhiro K
Matsushita H
Ando Y
Source :: Cell journal [Cell J] 2022 Apr; Vol. 24 (4), pp. 212-214. Date of Electronic Publication: 2022 Apr 27.
Publication Year :: 2022
Abstract: HASPIN acts in chromosome segregation via histone phosphorylation. Recently, HASPIN inhibitors have been shown to suppress growth of various cancer cells. Pancreatic cancer has no symptom in the early stages and may progress before detection. So, the 5-year survival rate is low. Here, we reported that administration of the HASPIN inhibitor, CHR-6494, to mice bearing pancreatic BxPC-3-Luc cancer cells significantly suppressed growth of BxPC-3-Luc cells. CHR-6494 might be a useful agent for treating pancreatic cancer.<br />Competing Interests: There is no conflict of interest in this study.<br /> (Copyright© by Royan Institute. All rights reserved.)

Full Text Access

Tools